JADEN HYSLIP: Open Payments
NPI 1104509892 · AMHERST, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,131 in 106 payments from 20 companies in 2025. Trend: 2023 $1,935 · 2024 $2,080 · 2025 $2,131
Food & beverage: $2,131
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $399 |
| Otsuka America Pharmaceutical, Inc. | 19 | $370 |
| Janssen Pharmaceuticals, Inc | 7 | $253 |
| Teva Pharmaceuticals USA, Inc. | 19 | $229 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $164 |
| Vanda Pharmaceuticals Inc. | 6 | $132 |
| Alkermes, Inc. | 6 | $127 |
| Lundbeck LLC | 6 | $95 |
| Bausch Health US, LLC | 2 | $46 |
| E.R. Squibb & Sons, L.L.C. | 2 | $43 |
Products named: INGREZZA, REXULTI, SPRAVATO, CAPLYTA, FANAPT, UZEDY, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across NY — which companies pay providers there.
